Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220792 · ClinicalTrials.gov registry record · Phase 3
Group Therapy for Primary Breast Cancer
A Phase 3 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
NCT00220792: Completed Phase 3 study, sponsored by Stanford University.
NCT00220792 is a Phase 3 study that has completed, run by Stanford University. The registered enrollment target is 480 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00220792, a Phase 3 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether women with primary breast cancer who were randomly assigned to receive a brief group therapy would show a greater reduction in mood disturbance over time compared to those randomized to the control condition. We also hypothesized that women who were highly distressed at baseline would show the greatest benefit from participating in a support group, and that therapists with more training and experience would be most effective in reducing distress.
Interventions
- BEHAVIORAL Brief supportive-expressive group therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 1993-06 |
| Est. Completion | 1998-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00220792
The ClinicalTrials.gov registry entry for NCT00220792 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brief supportive-expressive group therapy is the first listed.
NCT00220792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00220792 about?
NCT00220792 is a clinical study titled "Group Therapy for Primary Breast Cancer". The purpose of this study is to determine whether women with primary breast cancer who were randomly assigned to receive a brief group therapy would show a greater reduction in mood disturbance over time compared to those randomized to the control condition. We also hypothesized that women who were ...
What is the current status of trial NCT00220792?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 1993-06. Estimated completion is 1998-06.
What interventions are being tested in trial NCT00220792?
The interventions under investigation include: Brief supportive-expressive group therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00220792?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.